Pulmatrix, Inc.
Clinical-stage biopharma developing inhaled therapies for respiratory diseases.
PULM | US
Overview
Corporate Details
- ISIN(s):
- US74584P3010
- LEI:
- Country:
- United States of America
- Address:
- 945 CONCORD STREET, 1701 FRAMINGHAM
- Website:
- https://www.pulmatrix.com/
- Sector:
- Manufacturing
Description
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company that develops novel inhaled therapeutic products for respiratory and other diseases. The company's core is its proprietary iSPERSE™ technology, an engineered dry powder platform designed for efficient drug delivery directly to the lungs. This technology aims to improve therapeutic outcomes for patients with serious pulmonary conditions. The company's development pipeline has included candidates for diseases such as Chronic Obstructive Pulmonary Disease (COPD). In late 2024, Pulmatrix announced a proposed merger with Cullgen Inc., a company focused on targeted protein degradation, to form a combined entity with a diversified clinical pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Pulmatrix, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pulmatrix, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pulmatrix, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
